Trends in transfusion burden among long-term survivors of childhood hematological malignancies

References

• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543–552.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006;24: 4499–4506.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Zimmermann M, Reinhardt D, et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 2007;109:936–943.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730–2741.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010;24:345–354.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001;38:57–62.
   PubMed Web of Science ®Google Scholar
• Inati A, Musallam KM, Wood JC, et al. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood 2010;115:2980–2981; author reply 2981–2982.
   PubMed Web of Science ®Google Scholar
• Anderson L, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171–2179.
   PubMed Web of Science ®Google Scholar
• Thakerngpol K, Fucharoen S, Boonyaphipat P, et al. Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Biometals 1996;9:177–183.
   PubMed Web of Science ®Google Scholar
• Risdon R, Barry M, Flynn D. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia. J Pathol 1975;116:83–95.
   PubMed Web of Science ®Google Scholar
• Olivieri N, Nathan D, MacMillan J, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574–578.
   PubMed Web of Science ®Google Scholar
• Zurlo M, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27–30.
   PubMed Web of Science ®Google Scholar
• Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988;318:809–814.
   PubMed Web of Science ®Google Scholar
• Kazak AE, Hocking MC, Ittenbach RF, et al. A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer 2012;59:96–99.
   PubMed Web of Science ®Google Scholar
• Eng J, Fish JD. Insidious iron burden in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;56:368–371.
   PubMed Web of Science ®Google Scholar
• Ruccione KS, Mudambi K, Sposto R, et al. Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors. Pediatr Blood Cancer 2012;59:697–702.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009. Bethesda, MD: National Cancer Institute; 2012.
   Google Scholar
• Ness KK, Armenian SH, Kadan-Lottick N, et al. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol 2011;4:185–197.
   PubMed Web of Science ®Google Scholar
• Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 2008;111:5515–5523.
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2328–2338.
   PubMed Web of Science ®Google Scholar
• Kurt BA, Nolan VG, Ness KK, et al. Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. Pediatr Blood Cancer 2012;59:126–132.
   PubMed Web of Science ®Google Scholar
• Gurney J, Ness K, Sibley S, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006;107:1303–1312.
   PubMed Web of Science ®Google Scholar
• Link K, Moëll C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 2004;89:5003–5012.
   PubMed Web of Science ®Google Scholar
• Taskinen M, Saarinen-Pihkala U, Hovi L, et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000;356:993–997.
   PubMed Web of Science ®Google Scholar
• Sheth S. SQUID biosusceptometry in the measurement of hepatic iron. Pediatr Radiol 2003;33:373–377.
   PubMed Web of Science ®Google Scholar
• Fischer R, Piga A, Harmatz P, et al. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci 2005;1054:350–357.
   PubMed Web of Science ®Google Scholar
• Nielsen P, Engelhardt R, Düllmann J, et al. Non-invasive liver iron quantification by SQUID-biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis. Blood Cells Mol Dis 2002;29:451–458.
   PubMed Web of Science ®Google Scholar
• St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855–861.
   PubMed Web of Science ®Google Scholar
• Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106:1460–1465.
   PubMed Web of Science ®Google Scholar
• Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009;113:4853–4855.
   PubMed Web of Science ®Google Scholar